- Brensocatib shows consistent efficacy and safety across three prespecified subgroups in the ASPEN trial.
- Significant reduction in exacerbation rates across all subgroups compared to placebo.
- Improved lung function measurements in treated patients with non-cystic fibrosis bronchiectasis (NCFBE).
Insmed Incorporated (INSM, Financial) has revealed new data from the Phase 3 ASPEN trial for brensocatib, demonstrating consistent efficacy and safety across three prespecified subgroups in patients with non-cystic fibrosis bronchiectasis (NCFBE). These subgroups include adolescents, patients on macrolide therapy, and individuals with varying blood eosinophil levels.
In adolescents, both the 10mg and 25mg doses of brensocatib significantly reduced annualized exacerbation rates to 0.35 and 0.64 respectively, compared to 0.87 for placebo. Notably, 59% of the treated adolescent patients remained exacerbation-free versus 35% on placebo, highlighting brensocatib's effectiveness in this subgroup.
Among patients on macrolide therapy, brensocatib continued to show efficacy with lower exacerbation rates: 10mg resulted in rates of 0.97/1.21 and 25mg showed 0.98/1.21 compared to placebo rates of 1.23/1.54. The 25mg dosage also demonstrated reduction in forced expiratory volume (FEV?) decline across these subgroups.
Furthermore, the treatment was effective across varying blood eosinophil levels, with both doses reducing exacerbation rates and prolonging the time to first exacerbation. The 25mg dosage also improved lung function and quality of life scores, regardless of baseline eosinophil count.
These findings were part of Insmed's presentation of 11 new abstracts at the American Thoracic Society (ATS) 2025 International Conference, underscoring the potential of brensocatib as a foundational treatment for this complex and heterogeneous disease.
